Miniatura

Fitxers

725910.pdf (9.61 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-09-26

Llicència de publicació

cc-by (c) Gámez-Chiachio, Manuel et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/190151

Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13046-022-02497-w

Resum

Background: Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel efective targeted treatments for HER2/GSDMB aggressive tumors. Methods: Diferent in vitro approaches (immunoblot, qRT-PCR, fow cytometry, proteomic analysis, immunoprecipitation, and confocal/electron microscopy) were performed in HER2 breast and gastroesophageal carcinoma cell models. Results were then validated using in vivo preclinical animal models and analyzing human breast and gastric cancer samples. Results: GSDMB up-regulation renders HER2 cancer cells more resistant to anti-HER2 agents by promoting protective autophagy. Accordingly, the combination of lapatinib with the autophagy inhibitor chloroquine increases the therapeutic response of GSDMB-positive cancers in vitro and in zebrafsh and mice tumor xenograft in vivo models. Mechanistically, GSDMB N-terminal domain interacts with the key components of the autophagy machinery LC3B and Rab7, facilitating the Rab7 activation during pro-survival autophagy in response to anti-HER2 therapies. Finally, we validated these results in clinical samples where GSDMB/Rab7/LC3B co-expression associates signifcantly with relapse in HER2 breast and gastric cancers. Conclusion: Our fndings uncover for the frst time a functional link between GSDMB over-expression and protective autophagy in response to HER2-targeted therapies. GSDMB behaves like an autophagy adaptor and plays a pivotal role in modulating autophagosome maturation through Rab7 activation. Finally, our results provide a new and accessible therapeutic approach for HER2/GSDMB+cancers with adverse clinical outcome.

Matèries

Càncer de mama, Resistència als medicaments, Tumors

Matèries (anglès)

Breast cancer, Drug resistance, Tumors

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

GÁMEZ-CHIACHIO, Manuel, MOLINA-CRESPO, Ángela, RAMOS-NEBOT, Carmen, MARTINEZ-VAL, Jeannette, MARTÍNEZ, Lídia, GASSNER, Katja, LLOBET, Francisco j., SORIANO, Mario, HERNANDEZ, Alberto, CORDANI, Marco, BERNADÓ-MORALES, Cristina, DIAZ, Eva, ROJO-SEBASTIAN, Alejandro, TRIVIÑO, Juan carlos, SANCHEZ, Laura, RODRIGUEZ BARRUECO, Ruth, ARRIBAS, Joaquín, LLOBET-NAVAS, David, SARRIÓ, David, MORENO-BUENO, Gema. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation. _Journal of Experimental & Clinical Cancer Research_. 2022. Vol. 41, núm. 1, pàgs. 285. [consulta: 23 de gener de 2026]. ISSN: 1756-9966. [Disponible a: https://hdl.handle.net/2445/190151]

Exportar metadades

JSON - METS

Compartir registre